Recent Updates
Recently added Catalysts

Apitox, purified honeybee toxin, lyophilized in saline

Phase 3

Osteoarthritis of the Knee | Monoclonal antibody | Musculoskeletal |Apimeds Pharmaceuticals US, Inc.|Last Updated: Dec 13, 2016

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment363

FDA Designations

No designations recorded

Clinical trial landscape

Apitox, purified honeybee toxin, lyophilized in saline · 1 trial · 1 indication

Phase 3 1
NCT01112722Apitox, Honeybee Toxin for Pain and Inflammation of OsteoarthritisOsteoarthritis of the Knee
COMPLETED363 Analytics
PHASE3COMPLETED
Apitox, Honeybee Toxin for Pain and Inflammation of Osteoarthritis
Osteoarthritis of the Knee
NCT01112722363
Unlock trial analytics

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
PurposeTREATMENT

Interventions

NameTypeDescription
Apitox, purified honeybee toxin, lyophilized in salineBIOLOGICALintradermal injections of 0.1mg apitox in 0.1ml WFI over 12 weeks treatment period, injections twice weekly range from 1 to 20 injections
histamineBIOLOGICALimitates pain and erythema of honeybee venom
Unlock Study Design Details

Competitive Landscape -Osteoarthritis 114 trials (matched to "Osteoarthritis of the Knee")

CompanyTickerTrialsLead PhaseDrugs
Eli Lilly and CompanyLLY3PHASE3Eloralintide
Pacira Biosciences, Inc.PCRX4PHASE3ZILRETTA
Novo Nordisk A/S Sponsored ADR Class BNVO1PHASE3NNC0487-0111
Bioventus, Inc. Class ABVS1PHASE2PTP-001
Enlivex Ltd.ENLV2PHASE1Allocetra
Smith & Nephew plc Sponsored ADRSNN9 - Undisclosed
Stryker CorporationSYK11N/AUndisclosed
Zimmer Biomet Holdings, Inc.ZBH57N/AUndisclosed
Merit Medical Systems, Inc.MMSI1N/ACorticosteroid
Johnson & JohnsonJNJ1N/AUndisclosed
Abbott LaboratoriesABT1N/AUndisclosed
Enovis CorporationENOV1N/AUndisclosed
Teleflex IncorporatedTFX1 - Undisclosed
Unlock Competitive Intelligence